The Virtual CVOT Summit 2025 will start on 20 November at 15:00 CET.The livestream will start today at 15:00 CET.Welcome and Introduction15:00 – 15:10 CETOliver Schnell (Munich, Germany)Progress in Heart Failure and the Growing Intersection of Cardiac and Kidney Disease15:10 – 15:25Scott Solomon (Boston, MA, USA)SURPASSing Previous Boundaries: Incretine Mimetics and Cardiorenal Outcomes15:25 – 15:45Stefano del Prato (Pisa, Italy)The Aldosterone Pathway Revisited: Novel Approaches in Hypertension Management15:45 – 16:00Michel Azizi (Paris, France)Discussion16:00 – 16:15Perspectives of the Guideline Workshop (1) Obesity: New Opportunities for Network Meta-Analyses16:15 – 16:30Arnav Agarwal (Hamilton, Canada)Perspectives of the Guideline Workshop (2) Implementation of Guidelines at National Level: Perspectives of the European Renal Association (ERA)16:30 – 16:45Christoph Wanner (Wuerzburg, Germany)Breaking Barriers in Hard to Control Hypertension: Key Insights for Practitioners16:45 – 17:00Kamlesh Khunti (Leicester, UK)Putting Person-Centered Care into Practice: What Matters to Patients with Chronic Liver Disease17:00 – 17:15Marko Korenjak (Brussels, Belgium)Discussion17:15 – 17:30Break17:30 – 17:45EU Policies to Improve Cardiovascular Health17:45 – 17:55MEP Romana Jerković (Brussels, Belgium)Towards an Inclusive EU CV Plan17:55 – 18:05Chantal Mathieu (Leuven, Belgium)Cardiovascular Health: How to Transition to National Progress18:05 – 18:15Dirk Müller-Wieland (Aachen, Germany)Introduction of the Award18:30 – 18:40Eberhard Standl (Munich, Germany)Laudation and Presentation of Awardee18:40 – 18:45Rury Holman (Oxford, UK)The Discovery of Multi-Receptor Drugs: The end of obesity and type 2 diabetes?18:45 – 19:25Matthias Tschöp (Munich, Germany)Closing19:25 – 19:30Rury Holman (Oxford UK), Eberhard Standl (Munich, Germany)OP 1: Prediabetes Remission and Long-Term Risk of Cardiovascular Death, Heart Failure Hospitalization, and All-Cause Mortality19:30 – 20:15Andreas Birkenfeld (Tuebingen, Germany)OP 2: Clinical association of diabetes mellitus and heart failure with metabolic dysfunction-associated steatotic liver diseaseKateryna Pivtorak (Vinnytsia, Ukraine)OP 3: Relationship between undiagnosed diabetes, cardiovascular events and mortality in acute coronary syndrome patients enrolled in the STRONG-MI registryFaisal Aziz (Graz, Austria)OP 4: Influence of Diabetes Mellitus on Thrombosis in Branch Retinal Vein OcclusionMarianne Shahsuvaryan (Yerevan, Armenia)Closing of Day 120:15 CETOliver Schnell (Munich, Germany)Thank you for your attendance and contribution. The livestream will continue tomorrow at 08:45 CET.Thank you for your attendance and contribution. The livestream will continue tomorrow at 08:45 CET.The livestream will start today at 08:45 CET.C-Peptide as a Surrogate Parameter for Residual Beta Cell Function in Type 1 Diabetes and its Potential Clinical Role08:45 – 09:00Colin M. Dayan (Cardiff, UK)Targeting Autoimmunity in Type 1 Diabetes: Emerging Disease-Modifying Strategies09:00 – 09:15Chantal Mathieu (Leuven, Belgium)Discussion09:15 – 09:30The Heartbeat of Glucose: CGM’s Role in Cardiovascular Outcomes in Diabetes09:30 – 09:45 Tadej Battelino (Ljubljana, Slovenia)Building CGM Expertise: Recommendations for Education and Practice09:45 – 10:00Pratik Choudhary (Leicester, UK)Continuous Ketone Monitoring: A New Era in Metabolic Management10:00 – 10:15Susanne Reger-Tan (Bad Oeynhausen, Germany)Discussion10:15 – 10:30 Break10:30 – 10:40 CETSatellite Symposium: See Further, Act Smarter: How AI Is Transforming Diabetes Care10:40 – 10:55 CETJohn Pemberton (Birmingham, UK) - Supported by Roche Diagnostics International Ltd.Break10:55 – 11:00 CETKidney Protection in Type 1 Diabetes: Are Non-Steroidal MRAs the Next Step? 11:00 – 11:15Hiddo Heerspink (Groningen, The Netherlands)SGLT2 Inhibitors and Non-Steroidal MRAs: Combining Forces for Cardiorenal Protection11:15 – 11:30Johannes Mann (Munich, Germany)Future Directions in the Treatment of Chronic Kidney Disease11:30 – 11:45Parminder Judge (Oxford, UK)Discussion11:45 – 12:00SGLT2 Inhibitors – Changing the Game in Heart Failure Treatment12:00 – 12:15Nikolaus Marx (Aachen, Germany)Changing Landscape in HFpEF: New Therapeutic Strategies12:15 – 12:30 Pardeep Jhund (Glasgow, UK)Emerging Treatment Strategies in HFrEF12:30 – 12:45Giuseppe Rosano (London, UK)Discussion12:45 – 13:00Break13:00 – 13:30Obesity 2025 – State of the Art in Diagnosis and Therapy13:30 – 13:45Timothy Garvey (Birmingham, AL, USA)One Target Is Not Enough? Novel GLP-1-Based Treatment Approaches13:45 – 14:00Sean Wharton (Toronto, Canada)Discussion14:00 – 14:15The Liver in Distress: Managing Obesity-Related MASLD14:15 – 14:30Elisabetta Bugianesi (Turin, Italy)Nutrition Under Incretin Therapy14:30 – 14:45Andreas Pfeiffer (Berlin, Germany)Discussion14:45 – 15:00Beyond LDL Lowering: Managing the Residual Risk in ASCVD15:00 – 15:15Peter Libby (Boston, MA, USA)Why Do We Need to Establish Cardio-Metabolic-Renal Care and Beyond?15:15 – 15:30Robert Eckel (Denver, CO, USA)Why Early Diagnosis Matters, and How to Put It into Practice in Chronic Kidney Disease15:30 – 15:45Ana Cebrian (Murcia, Spain)Supporting Patient Adherence – Practical Strategies for Clinical Practice15:45 – 16:00Katharine Barnard-Kelly (Hampshire, UK)Translating Guidelines into Practice: A Heart Failure Nurse’s Perspective16:00 – 16:15Ekaterini Lambrinou (Limassol, Cyprus)Discussion16:15 – 16:30Break16:30 – 16:45Industry’s perspective - Panel Discussion16:45 – 17:45 CETOliver Schnell (Munich, Germany)OP 5: A Time In Range of 70% Attenuates the Senescence-Inducing and Pro-Inflammatory Effects of Hyperglycemia17:45 – 18:30Rosalba La Grotta (Milan, Italy)OP 6: Monitoring ketone levels continuously during a 7-day fastNina Jendrike (Ulm, Germany)OP 7: Routine Biopsychosocial Care Is Practical and AchievableKatharine Barnard-Kelly (Fareham, UK)OP 8: Pharmacist-Led Consultations for Continuous Glucose Monitoring Users: Knowledge, Confidence, and Opportunities to Support Diabetes Management and OutcomesAnastasija Levkina (Vilnius, Lithuania)Abstract Award and Closing18:30 – 18:45 CETOliver Schnell (Munich, Germany) Thank you for your attendance and contribution to the Virtual CVOT Summit 2025. See you next year for the 12th CVOT Summit on 19 - 20 November 2026. Thank you for your attendance and contribution to the Virtual CVOT Summit 2025. See you next year for the 12th CVOT Summit on 19 - 20 November 2026. We will be right back.We are currently having some technical issues. We will be right back.The page is automatically updated.The next program item is loaded.The next program item is loaded.
Virtual CVOT Summit 2026 12th Annual Congress on Cardiovascular, Kidney and Metabolic Outcome
